tiprankstipranks
Trending News
More News >
BeiGene (ONC)
NASDAQ:ONC
US Market

BeiGene (ONC) Earnings Dates, Call Summary & Reports

Compare
777 Followers

Earnings Data

Report Date
Aug 22, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
0.24
Last Year’s EPS
-1.15
Same Quarter Last Year
Based on 9 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 07, 2025
|
% Change Since: 8.55%
|
Next Earnings Date:Aug 22, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial and operational performance with significant revenue growth, market leadership, and pipeline advancements. Despite challenges in fixed-duration treatments and navigating a complex global environment, the company's strategic initiatives and investments are positioning it well for future growth.
Company Guidance
During the call, the company provided detailed guidance and updates across various metrics. For the first quarter of fiscal year 2025, they achieved revenue of $1.1 billion, marking a 49% growth compared to the previous year. The U.S. market saw a 60% increase, with BRUKINSA leading in new patient starts and achieving $563 million in sales, representing a 60% year-over-year growth. The company also achieved GAAP profitability for the first time, with significant improvements in operating profit and cash flow. They anticipate full-year revenue between $4.9 billion and $5.3 billion, maintaining a gross margin in the mid-80 percentile range. Additionally, they highlighted their robust pipeline progress, with over 10 proof-of-concept readouts expected across their solid tumor pipeline in 2025, and emphasized the strategic investments made to ensure supply chain resiliency, including an $800 million investment in a New Jersey manufacturing facility. The company also announced their redomiciling to Switzerland, reflecting their evolution into a globally diversified oncology leader.
Record-Breaking Revenue Growth
Global sales reached $1.1 billion in Q1 2025, marking a 49% increase from Q1 2024. The U.S. market alone grew by 60%, driven by strong demand for BRUKINSA.
BRUKINSA's Market Leadership
BRUKINSA became the market leader by revenue in the U.S. BTK market, with Q1 2025 sales reaching $563 million, a 60% growth compared to the previous year. It surpassed competitors in new patient starts for CLL.
GAAP Profitability Achieved
For the first time, the company achieved GAAP profitability, with net income showing significant improvement from the previous year.
Robust Pipeline Progress
The company is advancing a strong pipeline, including the BTK CDAC and sonro, with multiple Phase III trials initiated and more than 10 proof-of-concept readouts expected in 2025.
Global Expansion and Growth
Significant sales growth was seen in Europe (75% increase) and the rest of the world (146% increase), driven by new launches and market expansion.

BeiGene (ONC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ONC Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 22, 2025
2025 (Q2)
0.24 / -
-1.15
May 07, 2025
2025 (Q1)
-0.53 / 0.00
-2.41
Mar 27, 2025
2024 (Q4)
-1.01 / -1.43
-3.5359.49% (+2.10)
Nov 12, 2024
2024 (Q3)
-1.11 / -1.15
2.01-157.21% (-3.16)
Aug 27, 2024
2024 (Q2)
-2.19 / -1.15
-3.6468.41% (+2.49)
May 08, 2024
2024 (Q1)
-3.09 / -2.41
-3.3427.84% (+0.93)
Feb 26, 2024
2023 (Q4)
-3.49 / -3.53
-4.2917.72% (+0.76)
Nov 09, 2023
2023 (Q3)
-3.38 / 2.01
-5.39137.29% (+7.40)
Aug 25, 2023
2023 (Q2)
-3.36 / -3.64
-5.5634.53% (+1.92)
May 04, 2023
2023 (Q1)
-3.66 / -3.34
-4.2421.23% (+0.90)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ONC Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 07, 2025
$241.75$232.25-3.93%
Mar 27, 2025
$250.92$262.60+4.65%
Nov 12, 2024
$205.04$193.64-5.56%
Aug 27, 2024
$199.22$202.17+1.48%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BeiGene (ONC) report earnings?
BeiGene (ONC) is schdueled to report earning on Aug 22, 2025, TBA Not Confirmed.
    What is BeiGene (ONC) earnings time?
    BeiGene (ONC) earnings time is at Aug 22, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ONC EPS forecast?
          ONC EPS forecast for the fiscal quarter 2025 (Q2) is 0.24.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis